Presentations
Recombinant Animal-Free Albumin Enhances Infectious Lentiviral Vector Yields – ASGCT 2026 Presentation
PDF · Published 2026-11-14 · 2 min read
Presentation
Lentiviral vector (LVV) manufacturing loses an estimated 70–80% of infectious titer across downstream processing. The losses are cumulative and mechanical: thermal decay during process holds, non-specific adsorption to depth filters, membranes and tubing, shear during tangential flow filtration, and envelope damage through freeze-thaw. In this ASGCT 2026 talk, InVitria presented data showing that 1% Optibumin® 25 recombinant human serum albumin (rHSA) preserves infectious LVV titer across every one of these unit operations.
The rationale is a regulatory precedent rather than a hypothesis. InVitria recombinant albumin is the stabilizer in Merck’s ERVEBO® (Ebola Zaire Vaccine, Live), a VSV-pseudotyped enveloped virus approved by FDA, EMA and PMDA in December 2019. VSV-G pseudotyped lentiviral vectors share the same lipid envelope, the same surface glycoprotein and the same fragility.
Unit operations tested
VSV-G pseudotyped LVV was exposed to stressors relevant to commercial virus manufacturing, with or without 1% (m/v) rHSA. Genomic titer was measured by RT-qPCR against an RNA standard; infectious titer was measured by transduction of HT-1080 cells with GFP-encoding LVV using live-cell imaging. All samples came from the same virus batch and were compared against an unstressed control.
- Process hold — 24 hours at room temperature or 4 °C
- Clarification — Millistak depth filtration
- Tangential flow filtration — 5× concentration on a 500 kDa membrane
- Sterile filtration — controlled flow through a 0.2 µm PES filter
- Cryopreservation — freeze-thaw at −80 °C
Key results
- Process holds: ~4× higher genomic titer at room temperature and ~2.5× at 4 °C versus buffer alone; ~50% of infectious titer preserved after 24 hours at 4 °C.
- Extended room-temperature holds (third-party collaborator data): ~86% of infectious titer retained at 24 hours with 2% Optibumin® 25, and usable stability extended to 48 hours. Without albumin, infectivity fell below the limit of quantitation by 24 hours.
- Clarification: ~70% genomic and ~70% infectious titer retained through depth filtration, roughly 1.4× the recovery of the buffer-only control.
- Tangential flow filtration: ~1.5× higher recovered infectious titer and a 100× reduction in virus lost to permeate — direct evidence of cassette membrane passivation. Genomic titer loss was 0% with 1% rHSA versus ~50% without.
- Sterile filtration: ~3× higher infectious titer recovery and ~4× higher genomic titer retention with a 1% Optibumin® 25 pre-coat, achieved with a 5-minute filter passivation step. The infectious-to-genomic ratio was preserved at 0.36%, within the typical 0.1–1% range, confirming particle quality.
- Cryopreservation: genomic titer matched the no-freeze reference (~100% retained) and infectious recovery was ~4× the buffer-only control (47% versus 12% retained).
Why one excipient addresses several failure modes
Albumin is a surface-active, chemically defined protein that passivates membranes and tubing, prevents aggregation, buffers shear and provides thermal and cryo-protection. Optibumin® 25 is an animal-free, chemically defined rHSA supplied as a 25% w/v solution with no stabilizers or preservatives and 99% reduced Cys34, manufactured to cGMP excipient grade — so the same drop-in addition addresses shear protection, surface passivation, anti-aggregation, cryoprotection and thermal stabilization without reformulating the process.
Presentation details
Presented by Mark Stathos, PhD at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, Abstract #90, 12 May 2026. Co-authors: Wren Michaels, PhD; Jacob Weber, PhD; Zebulun Huseman; Neftali Zapata; Marcus Curl; Vladimir Akoyev, PhD. InVitria, Junction City, KS.
Download
Download PDFProducts Mentioned
-
Optibumin® 25
Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.
-
Optibumin® 20
High-purity recombinant human serum albumin excipient, a 20% w/v liquid for cell processing, cryopreservation, and final formulation.
-
Exbumin®
Approved excipient recombinant human serum albumin, supplied as a lyophilized powder for therapeutic formulation, vaccine stabilization, and viral vector processing.
More resources
Keep reading.
M2SR Cell-Based Flu Vaccine and Platform for Infectious Diseases – WVC 2023 Presentation
From Licensed Precedent to Next-Generation Ebola Vaccines – WVC Europe 2026 Presentation
Talk to a Scientist
See how rHSA performs in your media.
Send us your cell line and formulation and we will help you design a side-by-side evaluation against your current albumin.